AIM2 and bladder transitional cell carcinoma: These findings reveal a previously unappreciated role of AIM2 inflammation activation in BLCA cells in restricting cancer progression and suggest that AIM2 inflammasome activation could be applied to BLCA immunotherapeutic strategy.